MetaCap

Arrowhead Pharmaceuticals (ARWR) vs Grifols S.A. (GRFS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arrowhead Pharmaceuticals (ARWR) has outperformed Grifols S.A. (GRFS) over the past year, gaining 2.3% versus a loss of 3.0%. Over five years, GRFS leads with a -25.3% price change compared with -42.6% for ARWR. Arrowhead Pharmaceuticals is the larger company by market cap ($5.85 billion vs $5.55 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARWR+2.27%GRFS-2.98%
+128%+53%-23%
Nov 21, 20251 yearNov 20, 2026
ARWR-41.82%GRFS-31.40%
+29%-31%-90%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARWR versus GRFS key metrics
MetricARWRGRFS
Share price$41.37$8.15
Market cap$5.85B$5.55B
1-day change-5.22%-0.61%
YTD return-37.69%-12.83%
1-year return+2.27%-2.98%
5-year return-42.56%-25.30%
P/E ratio (TTM)—9.82
Forward P/E—6.55
EPS (TTM)$-5.11$0.83
Dividend yield0.00%1.30%
Annual dividend$0.00$0.00
Revenue (latest FY)$450.82M—
Revenue growth (YoY)-45.65%—
Net income (latest FY)$-724.21M—
Operating margin-156.86%—
Net margin-160.64%—
52-week high$95.49$9.77
52-week low$40.43$6.96
Distance from 52-week high-56.68%-16.58%
Analyst consensusstrong_buybuy
Avg. price target upside+156.39%+27.24%
Average volume2.08M628.64K
Shares outstanding141.37M258.22M
Employees1,06225,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Grifols S.A. offers a meaningfully higher dividend yield (1.30% vs 0.00%).

About Arrowhead Pharmaceuticals

ARWR stock →

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,062 employees

About Grifols S.A.

GRFS stock →

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.

Health Care · Biotechnology: Pharmaceutical Preparations · 25,000 employees

ARWR vs GRFS FAQ

Which is bigger, Arrowhead Pharmaceuticals or Grifols S.A.?

Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $5.85B compared with $5.55B for Grifols S.A. (GRFS).

Which stock has performed better over the past year, ARWR or GRFS?

ARWR returned +2.27% over the past 12 months, compared with -2.98% for GRFS (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Arrowhead Pharmaceuticals or Grifols S.A.?

Grifols S.A. pays a dividend yielding 1.30%, while Arrowhead Pharmaceuticals does not currently pay a regular dividend.

Are Arrowhead Pharmaceuticals and Grifols S.A. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons